ACT-GLOBAL Adaptive Platform Trial for Stroke
Launched by THE GEORGE INSTITUTE · Apr 2, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The ACT-GLOBAL trial is a research study aimed at finding better treatments for stroke, a condition that causes millions of deaths and disabilities worldwide. This trial is unique because it tests multiple treatment options at the same time to see which ones work best for stroke patients. The goal is to discover effective interventions that can be widely used to improve outcomes for people who have had a stroke.
To participate in this trial, individuals must be at least 18 years old and have a clinical diagnosis of stroke. There are no specific exclusions based on other health conditions, which means a wide variety of patients can potentially join. Participants in the trial can expect to be part of a global effort to improve stroke care, and they will help researchers gather valuable information on different treatment options. If you're considering joining, know that your participation could contribute to significant advancements in stroke treatment.
Gender
ALL
Eligibility criteria
- Platform Inclusion Criteria:
- • 1. Age ≥18 years
- • 2. Clinical diagnosis of stroke
- Platform Exclusion Criteria:
- • There are no platform level exclusion criteria
- • Each state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfill the overall platform criteria will be assessed for enrollment into each active domain.
About The George Institute
The George Institute for Global Health is a leading research organization dedicated to improving health outcomes through innovative clinical trials and groundbreaking research. Based in Australia, the institute focuses on addressing major health challenges, particularly in the areas of chronic diseases, cardiovascular health, and health equity. With a commitment to translating scientific discoveries into real-world applications, The George Institute collaborates with global partners to advance knowledge and implement effective health interventions. Its multidisciplinary team of researchers employs rigorous methodologies to ensure high-quality evidence that informs policy and practice, ultimately striving to enhance public health on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Patients applied
Trial Officials
Craig Anderson, MD, PhD
Principal Investigator
The George Institute
Bijoy Menon, MD
Principal Investigator
University of Calgary
Michael D Hill, MD
Principal Investigator
University of Calgary
Andrew Demchuk, MD
Principal Investigator
University of Calgary
Xiaoying Chen, PhD
Principal Investigator
The George Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported